Glioma News and Research RSS Feed - Glioma News and Research

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).
Drugs that block NOTCH signaling in many cancers could be effective against ACC

Drugs that block NOTCH signaling in many cancers could be effective against ACC

Using a novel cell culture approach, Yale Cancer Center researchers have discovered critical vulnerabilities in adenoid cystic carcinoma (ACC), a rare and lethal glandular cancer with a high recurrence rate and few treatment options. [More]
Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

New clinical-trial findings show that patients with a low-grade form of brain cancer who are treated with radiation plus a combination of chemotherapy drugs have better survival than patients treated with radiation alone. [More]
Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer progression-free survival and overall survival than patients who received radiation therapy alone, according to the results of the clinical trial, Radiation Therapy Oncology Group 9802 published in the April 7 issue of the New England Journal of Medicine. [More]
Altered metabolism of two essential amino acids helps drive development of glioblastoma

Altered metabolism of two essential amino acids helps drive development of glioblastoma

The altered metabolism of two essential amino acids helps drive the development of the most common and lethal form of brain cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Tews Laboratory uses LaVision BioTec UltraMicroscope to study molecular mechanisms of tumor invasion

Tews Laboratory uses LaVision BioTec UltraMicroscope to study molecular mechanisms of tumor invasion

LaVision BioTec, developers of advanced microscopy solutions for the life sciences, report on the work in the Tews Laboratory which is studying the molecular mechanisms of tumor invasion using an UltraMicroscope for enhanced imaging of cells. [More]
Cell-based immunotherapy may offer new hope in fight against brain cancer

Cell-based immunotherapy may offer new hope in fight against brain cancer

High-grade glioma is the most aggressive form of brain cancer. Despite improvements in surgical procedures, chemotherapy, and radiotherapy, this type of brain tumour is still notoriously hard to treat: less than 10% of patients survive beyond five years. [More]
Multimodal MRI recommended to prevent brain mass misdiagnosis

Multimodal MRI recommended to prevent brain mass misdiagnosis

T2*-weighted gradient recalled echo or susceptibility-weighted imaging sequences should be performed during the diagnosis of brain masses to rule out pseudotumoural presentation of cerebral amyloid angiopathy-related inflammation, say researchers. [More]
Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Stopping the growth of blood vessels in tumours is a key target for glioblastoma therapies, and imaging methods are essential for initial diagnosis and monitoring the effects of treatments. While mapping vessels in tumours has proven a challenge, researchers have now developed a combined magnetic resonance imaging (MRI) and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible. [More]
MYB-QKI fusion gene that drives pediatric low-grade gliomas poses a triple threat

MYB-QKI fusion gene that drives pediatric low-grade gliomas poses a triple threat

Oncology researchers have discovered that an abnormal fused gene that drives pediatric brain tumors poses a triple threat, operating simultaneously through three distinct biological mechanisms—the first such example in cancer biology. [More]
Researchers identify definitive genetic defect in angiocentric gliomas

Researchers identify definitive genetic defect in angiocentric gliomas

Diagnosis and treatment decisions for a recently recognized type of children's brain tumor should be improved by the discovery of the genetic mechanism that causes it, say researchers who identified the unusual DNA abnormality in angiocentric gliomas. [More]
Multinational study suggests new way to classify gliomas

Multinational study suggests new way to classify gliomas

A comprehensive analysis of the molecular characteristics of gliomas—the most common malignant brain tumor—explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years. [More]
Study provides detailed new information about diffuse glioma

Study provides detailed new information about diffuse glioma

An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes. [More]
Researchers reveal totally new biological mechanism that underlies cancer

Researchers reveal totally new biological mechanism that underlies cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate dehydrogenase (IDH) genes, the team uncovered some unusual changes in the instructions for how the genome folds up on itself. [More]
Novel 'hypnosedation' technique offers new option for patients undergoing awake surgery for gliomas

Novel 'hypnosedation' technique offers new option for patients undergoing awake surgery for gliomas

Could hypnosis help to reduce the psychological trauma associated with "awake craniotomy" for brain cancers? A new "hypnosedation" technique offers a new alternative for patients undergoing awake surgery for gliomas, suggests a study in the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons, published by Wolters Kluwer. [More]
New nanotechnology approach could transform gliomas from death sentence into treatable condition

New nanotechnology approach could transform gliomas from death sentence into treatable condition

An MRI contrast agent that can pass through the blood-brain barrier will allow doctors to detect deadly brain tumors called gliomas earlier, say Penn State College of Medicine researchers. This ability opens the door to make this fatal cancer treatable. [More]
Experimental drugs that modify cell metabolism also halt tumor growth

Experimental drugs that modify cell metabolism also halt tumor growth

Experimental drugs that alter cell metabolism also halted tumor growth and extended survival in mice with cancers linked to changes in the same gene, according to a new study led by researchers at NYU Langone Medical Center, its Laura and Isaac Perlmutter Cancer Center and Massachusetts General Hospital. [More]
TGen: PPF drug could help treat patients with deadly brain cancer

TGen: PPF drug could help treat patients with deadly brain cancer

In a significant breakthrough, the Translational Genomics Research Institute has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer. [More]
Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene. [More]
FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans. [More]
Researchers discover five new genetic variants associated with brain cancer

Researchers discover five new genetic variants associated with brain cancer

The biggest ever study of DNA from people with glioma - the most common form of brain cancer - has discovered five new genetic variants associated with the disease. [More]
Advertisement
Advertisement